Mirova US LLC Sells 257,551 Shares of Danaher Corporation $DHR

Mirova US LLC cut its holdings in Danaher Corporation (NYSE:DHR) by 18.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,169,205 shares of the conglomerate’s stock after selling 257,551 shares during the period. Danaher comprises approximately 2.4% of Mirova US LLC’s portfolio, making the stock its 19th biggest holding. Mirova US LLC owned about 0.16% of Danaher worth $230,965,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DHR. Nuveen LLC bought a new position in Danaher during the first quarter valued at $833,941,000. Invesco Ltd. grew its holdings in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Baird Financial Group Inc. grew its holdings in Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares during the period. Generation Investment Management LLP grew its holdings in Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after purchasing an additional 791,662 shares during the period. Finally, Parnassus Investments LLC grew its holdings in Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after purchasing an additional 722,636 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.5%

Shares of NYSE:DHR opened at $208.63 on Wednesday. The stock’s 50-day moving average price is $200.40 and its 200-day moving average price is $197.32. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The stock has a market capitalization of $149.39 billion, a P/E ratio of 44.39, a price-to-earnings-growth ratio of 3.02 and a beta of 0.77. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period last year, the firm earned $1.72 earnings per share. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DHR shares. Barclays reissued an “overweight” rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wells Fargo & Company dropped their target price on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Bank of America dropped their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $246.74.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.